Skip to main content

Advertisement

Table 7 Comparison of key results with previous studies

From: Estimating the returns to United Kingdom publicly funded musculoskeletal disease research in terms of net value of improved health outcomes

  MSD Cancer CVD
Average annual research investment
(for years of data used in IRR calculation as reported in source publications, using different time period for calculating constant prices and therefore not suitable for comparisons)
£70 m
(1978–1997, in constant 2013–2014 prices)
£266 m
(1976–1995, in constant 2011–2012 prices)
£111 m
(1975–1998, in constant 2005–2006 prices)
Average annual research investment
(rebased in same constant prices for comparative purposes)
£70 m
(1978–1997, in constant 2013–2014 prices)
£290 m
(1976–1995, in constant 2013–2014 prices)
£133 m
(1975–1998, in constant 2013–2014 prices)
Elapsed time
(between spending on research and health gain)
16 years 15 years 17 years
Attribution
(proportion of papers that include a United Kingdom address from the papers cited on guidelines)
30% 17% 17%
Average NMB
(for years of data used in IRR calculation as reported in source publications, but using different time period for calculating constant prices therefore not suitable for comparisons)
£801 m
(1994–2013, in constant 2013–2014 prices)
£6223 m
(1991–2010, in constant 2011–2012 prices)
£2949 m
(1992–2005, in constant 2005–2006 prices)
Average NMB
(rebased in same constant prices for comparative purposes)
£801 m
(1994–2013, in constant 2013–2014 prices)
£6458 m
(1991–2010, in constant 2013–2014 prices)
£3559 m
(1992–2005, in constant 2013–2014 prices)
IRR (health gain) 7% 10% 9%
  1. CVD cardiovascular disease, IRR internal rate of return, MSD musculoskeletal disease, NMB net monetary benefit